Ketamine for OCD: What Does the Evidence Show? Rapid Effects, Research Status, Risks, and Limitations

Ketamine has become one of the most discussed experimental medications in obsessive-compulsive disorder because its effects, when they occur, can begin within hours. That speed is clinically unusual in a disorder whose established medication treatments often require weeks before their full benefit can be judged. The central question is therefore not whether ketamine can change OCD symptoms at all. Small controlled studies show that it can in at least some people. The harder questions are how reliably it works, who benefits, how long improvement lasts, how repeated treatment should be handled, and whether rapid symptom change translates into durable recovery.

As of September 2026, the most accurate evidence-based description is this: racemic ketamine has a credible rapid anti-obsessional signal, including positive randomized data, but the evidence base remains small, heterogeneous, and dominated by short follow-up. The newest systematic review, published in August 2026, included 15 studies and 118 participants; another 2026 systematic review using narrower eligibility criteria included only five clinical trials. Current CANMAT/ICOCS international OCD guidelines place intravenous ketamine monotherapy as a third-line option and emphasize the limited and often transient evidence. Ketamine is not FDA-approved for OCD.

This article focuses on clinical evidence rather than promotional claims. It distinguishes racemic ketamine from esketamine, single-dose experiments from repeated-treatment protocols, symptom response from remission, OCD improvement from antidepressant effects, and controlled evidence from case reports. It also explains where ketamine fits beside established OCD care such as exposure and response prevention (ERP), cognitive behavioral therapy (CBT), clomipramine, augmentation strategies, and advanced interventions.

What Does the Evidence Show?

The evidence supports a rapid effect in a subset of patients rather than a dependable, durable response across the OCD population. In the best-known 2013 placebo-controlled trial, a single 0.5 mg/kg intravenous infusion produced significant acute improvement in obsessions, and 50% of the eight participants who received ketamine first met the study response criterion one week later, compared with none of the seven who received saline first. The trial was very small, enrolled drug-free adults with near-constant obsessions, and developed an unexpected carryover effect, so the investigators relied on first-phase data for the key between-group analysis.

A 2025 double-blind active-controlled crossover study added evidence from severe treatment-resistant OCD. Twelve participants were randomized and ten completed treatment with intramuscular racemic ketamine at 0.5 mg/kg and 1.0 mg/kg or fentanyl as an active control. Y-BOCS reductions were statistically greater and dose-related with ketamine, with the largest score changes at one to two hours and separation from the control extending across the one-week observation period. Two participants withdrew because they did not tolerate dissociative effects. The investigators described the result as preliminary and explicitly called for work on dosing and longer-term treatment.

The positive trials sit beside less favorable findings. In a 2012 open-label study of ten adults with treatment-refractory OCD, none met the prespecified OCD response criterion during the first three days after a single 0.5 mg/kg intravenous infusion. Mean OCD improvement was statistically detectable but less than 12%, while four of seven participants with comorbid depression had an antidepressant response. That study remains important because it shows why improvement in depression cannot automatically be counted as an anti-OCD effect.

Repeated dosing has not solved the durability question. A 2020 chart review of 14 inpatients receiving repeated intravenous ketamine found overall symptom reduction but only a minority reached a clinically meaningful response. A 2025 randomized study reported in European Psychiatry compared six ketamine infusions with six midazolam infusions in 30 treatment non-responders: 40% of the ketamine group met response criteria by the sixth infusion versus 20% with midazolam, yet only one ketamine participant, about 6%, maintained response four weeks after the final infusion. Because the latter report is a short conference publication rather than a large definitive trial, its results add to the signal without settling clinical practice.

Two systematic reviews published in 2026 reach a similar overall conclusion from different inclusion strategies. Heroiu and colleagues restricted their review to five trials—three randomized and two open-label—and found substantial short-term symptom reductions in some studies, with effects ranging from hours to six weeks. Eghdami and colleagues used broader criteria and included 15 studies with 118 participants, including case reports. They found rapid responses in randomized studies but emphasized that ketamine monotherapy benefits were commonly transient. The larger study count therefore reflects broader evidence capture, not a sudden expansion into a large, mature trial literature.

Why Ketamine Is Being Studied for OCD

OCD treatment has a speed problem and a nonresponse problem. ERP can produce large and durable improvements, and serotonin reuptake inhibitors are established pharmacological treatments, but both require sustained treatment. Some people remain substantially symptomatic after adequate evidence-based care. This creates a rational research space for interventions that work through different neurobiological pathways and may alter symptoms quickly.

Ketamine is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that alters glutamatergic signaling. Glutamate has long been investigated in cortico-striato-thalamo-cortical circuits implicated in OCD, so researchers asked whether a drug with rapid effects on glutamate-related signaling might produce a faster change in obsessions and compulsions than conventional serotonergic treatment. That hypothesis is biologically plausible, but a plausible mechanism is not evidence of clinical efficacy. The treatment question still depends on controlled outcomes, tolerability, relapse, and long-term safety.

This distinction matters because mechanistic language can easily become stronger than the evidence. Ketamine affects NMDA signaling and downstream synaptic processes, but current OCD trials do not establish a single mechanism that explains clinical improvement. Changes in glutamate signaling, plasticity, learning, salience, mood, and network dynamics are active research hypotheses rather than a clinically validated explanation for why one patient responds and another does not.

Ketamine, Esketamine, and Route of Administration

“Ketamine treatment” is not one standardized intervention. Racemic ketamine contains two mirror-image forms, R-ketamine and S-ketamine. Esketamine is the S-enantiomer. The OCD literature has used intravenous, intramuscular, oral, and intranasal approaches, with different doses, schedules, comparators, and populations. Results from one route cannot simply be transferred to another because exposure, peak concentration, tolerability, supervision, and the research base differ.

Most of the controlled OCD evidence concerns racemic ketamine given intravenously or intramuscularly. Oral ketamine has been studied mainly in small continuation work. Intranasal esketamine has a separate and much thinner OCD evidence base. The current FDA-approved esketamine product, Spravato, is approved for treatment-resistant depression in adults and for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior under its labeled conditions; OCD is not an approved indication.

The distinction is especially important when commercial services use “ketamine,” “esketamine,” “nasal ketamine,” and “ketamine therapy” as if they were interchangeable. A person reading a study of monitored intravenous racemic ketamine cannot assume that the same evidence supports a compounded lozenge used at home, an intranasal compounded formulation, or a Spravato protocol designed for depression.

What the Clinical Studies Actually Found

The 2012 open-label trial: small OCD change, stronger depression change

Bloch and colleagues gave a single 0.5 mg/kg intravenous ketamine infusion over 40 minutes to ten adults with treatment-refractory OCD. Response was defined as more than a 35% improvement in OCD symptoms within one to three days. None of the ten met that OCD response threshold. OCD scores improved by less than 12% on average during the early post-infusion period, while four of seven participants with comorbid depression met the antidepressant response criterion. The result demonstrated that ketamine could have different effects on depressive and obsessive-compulsive symptoms in the same patient.

The 2013 randomized crossover trial: the strongest early proof-of-concept signal

Rodriguez and colleagues randomized 15 drug-free adults with OCD and near-constant obsessions to intravenous ketamine 0.5 mg/kg or saline, with crossover planned at least one week later. Ketamine reduced obsession severity during the infusion. At one week, four of eight people who received ketamine first met a 35% or greater Y-BOCS reduction, compared with zero of seven who received placebo first. A carryover effect complicated the planned crossover analysis, so the most informative comparison came from the first treatment phase. The study established proof of concept; its sample and selection criteria prevent a population-level estimate of response probability.

Repeated intravenous treatment: signals with weak durability

A retrospective 2020 series examined 14 inpatients with SRI-resistant OCD who received a mean of about five ketamine infusions. Group scores improved, yet clinically meaningful response was uncommon. The design had no randomized control group, making regression to the mean, concurrent care, expectancy, and selection effects difficult to separate from the medication effect.

The 2025 randomized midazolam-controlled report tested six alternate-day infusions in 30 treatment non-responders. Acute response appeared after the first infusion for some participants, and response was more common after the full course in the ketamine group than in the comparator group. Four weeks later, durable response was rare. This pattern—fast change followed by substantial loss of benefit—is exactly why acute response and maintenance efficacy must be treated as different questions.

The 2025 intramuscular trial: active control and dose-related symptom change

Beaglehole and colleagues used fentanyl as a psychoactive active control rather than an inert placebo, strengthening the attempt to separate drug-specific effects from the experience of receiving an acutely noticeable medication. Ketamine produced greater dose-related Y-BOCS reductions, peaking around one to two hours. Benefits were still visible in the trajectory through one week, although residual effects at 168 hours were not consistently statistically significant. Dissociation was clinically important: two of twelve randomized participants withdrew because they could not tolerate it.

Oral continuation: useful feasibility data, not proof of maintenance treatment

A 2025 open-label extension followed participants from ketamine trials for up to six weeks with individualized oral ketamine schedules. Only a small number of participants with OCD entered and fewer completed the full period. The study contributes information about feasibility and longer exposure, but its open-label design and tiny diagnostic subgroups cannot establish that oral ketamine is an effective maintenance treatment for OCD.

How Fast Can Ketamine Affect OCD Symptoms?

When ketamine helps, the defining feature is speed. Controlled studies have detected reductions in obsession or Y-BOCS ratings during the infusion or within one to two hours. The 2013 trial found acute improvement during infusion; the 2025 intramuscular trial found maximal score changes at one to two hours. The repeated-infusion report also observed early responders after the first session. These are substantially faster time courses than clinicians expect when initiating conventional OCD pharmacotherapy.

Speed does not tell us whether a treatment will become clinically useful over months or years. A medication can produce a rapid state change without producing sustained remission. OCD is typically chronic or recurrent, so durability, relapse prevention, functional recovery, and integration with behavioral treatment matter as much as the first 24 hours.

How Long Do the Effects Last?

For a single ketamine administration, the most reproducible limitation is that benefit often fades within days. In the 2013 trial, some participants remained responders at one week. In the 2025 intramuscular study, separation from the active comparator extended through the week-long observation window, but residual one-week effects were weaker than the acute changes. The August 2026 systematic review concluded that monotherapy effects were typically transient and often dissipated within about a week.

Reports of benefit lasting several weeks do exist, especially when repeated dosing or psychotherapy is added, but they come from much smaller and less definitive datasets. The June 2026 systematic review reported effect durations ranging from hours to six weeks across eligible trials. That range describes what has been observed under different study designs; it does not mean that a typical patient should expect six weeks of relief after one infusion.

The key unanswered maintenance questions are practical: whether repeated dosing preserves benefit, whether tolerance or adverse effects alter the balance over time, how frequently treatment would be needed, how relapse should be managed, and whether ketamine is most useful as a short window in which another intervention can be intensified rather than as a stand-alone long-term therapy.

Response, Remission, and What Y-BOCS Changes Mean

OCD trials commonly use the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) to quantify severity. A reduction of 35% or more is often used as a treatment-response threshold in adult trials. “Response” means a substantial reduction from baseline; it does not mean that OCD has disappeared, that the person is in remission, or that functional impairment has resolved.

This is especially important in ketamine research because very rapid score changes can look dramatic. A person can cross a response threshold for hours or days and later return toward baseline. A rating-scale change also does not establish or remove an OCD diagnosis by itself. Diagnosis depends on the full clinical picture, including the nature of obsessions and compulsions, distress, time consumption, impairment, differential diagnosis, and clinical assessment.

Does Ketamine Work for Treatment-Resistant OCD?

Much of the ketamine literature specifically targets severe or treatment-resistant OCD, but “treatment-resistant” has not been defined identically across every study. Participants have often failed multiple serotonin reuptake inhibitor trials, ERP, clomipramine, or augmentation strategies, yet the exact number, dose adequacy, treatment duration, psychotherapy quality, and comorbidities vary.

The strongest current conclusion is therefore conditional: treatment resistance is the population in which ketamine is most clinically relevant, and controlled trials show that some highly symptomatic patients can improve rapidly. Evidence still does not identify a reliable responder profile. We do not have validated biomarkers, symptom dimensions, clinical characteristics, or prior-treatment patterns that tell a clinician in advance who will benefit.

For readers trying to understand what comes after unsuccessful first-line care, ketamine belongs in a broader treatment-resistance pathway rather than a separate shortcut. Established steps include optimizing evidence-based psychotherapy, adequate medication trials, and evidence-supported augmentation. Advanced care may involve intensive treatment settings or, in carefully selected severe refractory cases, neuromodulation such as deep brain stimulation.

What About Esketamine (Spravato) for OCD?

Esketamine deserves its own evidence category. It is the S-enantiomer of ketamine and has an FDA-approved intranasal product for specific depressive indications. That regulatory approval does not extend to OCD. Evidence for obsessive-compulsive symptoms has consisted mainly of case-level and small observational reports rather than the controlled OCD trial base available for racemic ketamine.

A 2026 prospective case series followed eight adults with severe treatment-resistant OCD and comorbid major depressive disorder who received intranasal esketamine 56–84 mg under a 12-week depression protocol. All had previously failed at least two adequate SSRI trials, clomipramine, CBT with ERP, and at least one pharmacological augmentation strategy. Mean Y-BOCS scores fell 30.3%, and four of eight met the study OCD response criterion. Depressive symptoms improved more strongly and earlier than OCD symptoms. Because every participant had severe comorbid depression and there was no control group, the study is hypothesis-generating rather than proof that esketamine is an established OCD treatment.

The 2026 CANMAT/ICOCS guidelines reflect this evidence gap: intravenous ketamine monotherapy receives a third-line position, while the evidence available for intranasal ketamine and esketamine is too limited for a comparable recommendation. The most recent esketamine case series appeared after much of the guideline evidence review and adds prospective data, but eight uncontrolled cases do not change the basic uncertainty.

Ketamine and ERP: Can a Rapid Drug Effect Create a Therapeutic Window?

One of the most interesting ideas in this field is that ketamine may be more useful as a temporary window for learning than as a stand-alone symptom suppressor. ERP works by helping a person approach obsessional triggers and uncertainty while reducing rituals, avoidance, reassurance seeking, and other compulsive responses. If ketamine temporarily changes distress, cognitive flexibility, or learning-related processes, researchers have hypothesized that ERP delivered during that period might consolidate gains.

A small 2016 proof-of-concept study examined whether exposure-based CBT could extend improvement after intravenous ketamine. The design was open-label and the sample was very small, so it cannot establish a ketamine-ERP synergy. Newer reviews point to longer outcomes in some combined protocols, but the data remain too limited to infer that adding ketamine reliably enhances ERP. The scientifically defensible interpretation is that this is a promising treatment-development hypothesis that requires adequately powered randomized trials comparing ketamine plus ERP with ERP plus an appropriate control.

For current clinical decision-making, ERP remains a core evidence-based OCD treatment on its own. Ketamine should not be presented as a prerequisite for doing ERP or as a way to bypass response prevention. When combination research is discussed, the behavioral treatment needs its own fidelity, dose, timing, and outcome measurement so that the contribution of each component can be understood.

How Might Ketamine Affect OCD?

Ketamine blocks NMDA receptors and rapidly changes glutamatergic signaling. Downstream effects can involve AMPA-related signaling, synaptic plasticity, and network-level changes. OCD research has long implicated cortico-striato-thalamo-cortical circuits and glutamate-related mechanisms, which provides a biological rationale for testing ketamine.

The mechanism of clinical improvement remains unsettled. A rapid reduction in obsessional intensity could arise through several interacting processes, including altered salience, affective state, cognitive flexibility, learning, or circuit dynamics. Dissociation itself is also an acute drug effect and complicates blinding. Current trials are not designed to prove that any one of these pathways causes the anti-OCD response. Mechanistic claims should therefore remain subordinate to the clinical data.

Where Ketamine Fits in Current OCD Treatment

The 2025 CANMAT/ICOCS international guidelines, published in the Journal of Psychiatric Research in 2026, provide the clearest current placement. They classify intravenous ketamine monotherapy as a third-line treatment and describe its evidence as limited, short-term, and potentially transient. They note that ketamine may be considered in clinical situations where rapid response is especially important, including severe symptoms after failure of first-, second-, and third-line treatments, while emphasizing safety screening and monitoring.

That placement is far downstream from routine first treatment. ERP and CBT remain foundational psychological interventions. Serotonergic medication strategies, including SSRIs and clomipramine, have a much larger evidence base and established clinical role. Antipsychotic augmentation has evidence for selected patients who remain symptomatic after adequate serotonergic treatment. These options differ in mechanism, speed, risk, and evidence quality, so “faster” is not the same clinical question as “better established.”

For severe chronic illness, treatment planning also involves level of care. Intensive outpatient, partial hospitalization, residential, or inpatient treatment may be appropriate when symptom burden, functioning, safety, medical needs, or treatment complexity require more structure. Ketamine does not replace the need to assess those dimensions.

Risks, Side Effects, and Monitoring

The acute adverse effects most relevant to psychiatric ketamine treatment include dissociation, perceptual changes, dizziness or sedation, nausea, increases in blood pressure and pulse, and impaired coordination or judgment. In the 2025 intramuscular OCD trial, dissociation was prominent enough for two participants to withdraw. FDA-approved ketamine labeling also describes cardiovascular stimulation and emergence reactions, and warns about respiratory depression and apnea with rapid intravenous administration of high doses.

Risk depends on dose, route, rate of administration, medical history, concurrent substances and medications, treatment frequency, and monitoring. This is one reason the controlled studies cannot be reduced to a dose copied from a paper. Research protocols use clinical screening, vital-sign monitoring, trained staff, and predefined criteria for managing adverse effects.

Repeated exposure raises additional questions. Ketamine is a Schedule III controlled substance in the United States and has abuse and dependence potential. FDA labeling and safety communications describe urinary tract and bladder injury in people with chronic use or abuse and hepatobiliary concerns with recurrent exposure. These risks are especially relevant when treatment moves from a single experimental dose toward repeated or maintenance schedules, because the long-term OCD-specific safety database is still sparse.

Esketamine carries its own labeled safety framework. Spravato has boxed warnings for sedation, dissociation, respiratory depression, and abuse and misuse, and it is distributed through a restricted REMS program with supervised administration and post-dose monitoring. Those requirements apply to the approved esketamine product and should not be casually projected onto every ketamine formulation; they nevertheless illustrate the level of supervision regulators consider necessary for this related drug.

Ketamine Clinics, Compounded Products, and At-Home Treatment

The marketplace is broader than the evidence. FDA has specifically warned about compounded ketamine products, including oral formulations, marketed for psychiatric disorders. Compounded drugs are not FDA-approved products, and FDA does not review them for safety, effectiveness, or quality before marketing in the same way it reviews approved drugs. FDA has also highlighted risks when compounded ketamine is used without on-site monitoring for sedation, dissociation, and changes in vital signs.

This matters for OCD because the research base is largely built from medically supervised protocols. A controlled IV or IM study does not validate mail-order lozenges, unsupervised home dosing, or a compounded nasal spray for OCD. A clinic can legally use an approved drug off label under appropriate medical practice, but legal availability and evidence for a specific indication are separate questions.

In 2026, FDA enforcement materials again stated that approved racemic ketamine is indicated as an anesthetic and is not FDA-approved for psychiatric disorders, while approved intranasal esketamine has specific depression indications. That regulatory distinction should be explicit whenever an OCD service advertises “ketamine” or “Spravato.”

Who Was Studied—and Who Was Not

The ketamine literature combines populations that differ in clinically important ways. The 2013 trial recruited drug-free adults with near-constant obsessions and limited psychiatric comorbidity. The 2012 trial included refractory patients with multiple comorbidities and produced much weaker OCD results. The 2025 intramuscular trial enrolled severe treatment-resistant cases. The 2026 esketamine series required both treatment-resistant OCD and major depressive disorder. These are not interchangeable populations.

The studies also remain overwhelmingly adult studies. They do not provide an adequate basis for routine pediatric ketamine treatment for OCD. Pregnancy, major medical comorbidity, substance-use risk, bipolar-spectrum vulnerability, psychotic disorders, and complex polypharmacy are also areas where eligibility criteria and safety concerns often narrow the research population. Real-world patients may therefore differ substantially from trial participants.

Another limitation is outcome timing. Studies that measure symptoms at one hour, 24 hours, one week, and six weeks answer different clinical questions. Acute changes in obsession ratings, weekly Y-BOCS response, sustained remission, return to work or school, family functioning, and long-term relapse are distinct outcomes. The current literature is strongest on acute symptom change and weakest on durable functional recovery.

What Researchers Still Need to Establish

The next generation of trials needs to be larger, parallel-group, adequately blinded, and long enough to measure relapse rather than only acute response. Active comparators are useful because ketamine produces noticeable psychoactive effects that can compromise blinding. Trials should prespecify response and remission definitions, include functional outcomes, and report concurrent psychotherapy and medication changes in enough detail to interpret the results.

Dose and route also need direct study. The evidence cannot currently tell us whether 0.5 mg/kg intravenous ketamine, lower or higher intramuscular dosing, oral maintenance, or another schedule offers the best balance of efficacy and tolerability. Repeated-treatment protocols need systematic monitoring of cognition, blood pressure, urinary symptoms, liver-related outcomes, misuse risk, and discontinuation effects over clinically meaningful periods.

Combination treatment is another major frontier. A rigorous ketamine-plus-ERP trial should test whether ketamine improves engagement, learning, or retention beyond what ERP achieves with an active placebo condition, and whether any incremental benefit survives after ketamine is stopped. This is more informative than simply asking whether symptoms are lower immediately after a psychoactive infusion.

Finally, prediction matters. If ketamine ultimately benefits only a subgroup, clinicians need markers that can be reproduced across studies. Candidate predictors might include symptom profile, treatment history, comorbid depression, acute dissociative response, cognitive measures, or biological markers, but none currently has sufficient validation for routine patient selection.

Practical Questions to Ask a Clinician or Ketamine Program

A serious clinical conversation should begin with the diagnosis and treatment history rather than with ketamine itself. The clinician should be able to explain how OCD was assessed, which evidence-based treatments have been tried adequately, whether current symptoms represent obsessions and compulsions rather than another condition, and why ketamine is being considered at this point in the treatment sequence.

Ask exactly which drug and route is proposed: racemic ketamine, FDA-approved esketamine, or a compounded product; intravenous, intramuscular, intranasal, or oral. Ask which OCD studies support that specific route and schedule. A claim based on “ketamine research” is too broad if the service being offered has not actually been studied in comparable OCD patients.

Ask how benefit will be measured. A program treating OCD should be able to track OCD symptoms with a validated scale such as the Y-BOCS and also assess functioning, compulsions, avoidance, and quality of life. Improvement in depression alone should not be presented as proof that OCD has responded.

Ask what happens after an acute response. A plan should address maintenance, relapse, established OCD therapy, adverse-effect monitoring, and what the clinician will do if the effect lasts hours or days rather than weeks. If ERP is part of the plan, ask how it is delivered, who provides it, and how response prevention is coordinated with the medication protocol.

Finally, ask about safety infrastructure: medical screening, vital-sign monitoring, observation after dosing, transportation restrictions, emergency procedures, substance-use screening, and follow-up for repeated exposure. For compounded products, ask why compounding is clinically necessary and what quality and monitoring safeguards apply.

Frequently Asked Questions

Does ketamine work for OCD?

It can reduce OCD symptoms rapidly in some people. Small randomized studies have shown significant anti-obsessional or Y-BOCS improvements, while other studies have found weak or inconsistent effects. The 2026 evidence base supports a real clinical signal and continuing research, but it does not provide a precise response rate that can be generalized to everyone with OCD.

How quickly can ketamine help OCD symptoms?

In positive studies, symptom changes have appeared during treatment or within one to two hours. Rapid onset is the most distinctive finding in this literature. The speed of onset does not predict how long the benefit will last.

How long does ketamine last for OCD?

After a single dose, benefit commonly lasts hours to days, and some participants in controlled studies remained improved at one week. Longer benefits have been reported with repeated dosing or combined treatment, but those data are smaller and less controlled. Durable maintenance remains an open research question.

Is ketamine FDA-approved for OCD?

No. FDA-approved racemic ketamine is approved as an anesthetic, not as a psychiatric treatment. Psychiatric use of racemic ketamine is off label. The absence of an OCD indication means FDA has not determined that a ketamine product is safe and effective specifically for OCD under an approved labeling framework.

Is Spravato approved for OCD?

No. Spravato is intranasal esketamine with FDA-approved indications related to treatment-resistant depression and depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior under its label. OCD is not an approved indication.

Can ketamine replace ERP?

Current evidence does not support replacing ERP with ketamine. ERP has a much larger OCD evidence base and remains a core treatment. Ketamine-plus-ERP is a research question: early pilot work suggests a possible way to extend rapid gains, but the combination has not been proven superior in adequately powered trials.

Does ketamine help intrusive thoughts?

Some of the strongest early data specifically measured rapidly changing obsessions or enrolled people with near-constant intrusive thoughts. That supports an anti-obsessional signal. It does not show that every form of intrusive thought responds to ketamine, and intrusive thoughts alone do not establish an OCD diagnosis.

Is ketamine better than SSRIs or clomipramine for OCD?

The current literature cannot support that conclusion. Ketamine can act much faster, but SSRIs and clomipramine have far larger evidence bases and established positions in OCD treatment. Comparative effectiveness requires direct trials that assess both benefit and risk over meaningful time periods, not a comparison of onset speed across unrelated studies.

Does ketamine work better when OCD and depression occur together?

That has not been established. Ketamine has stronger evidence for certain depressive indications than for OCD, and a patient with both conditions may experience different changes in each symptom domain. The 2012 OCD study found much stronger antidepressant than anti-OCD effects, while the 2026 esketamine case series found depression improved more strongly and earlier than OCD. Both conditions should therefore be measured separately.

Is at-home ketamine supported by the OCD trials?

The controlled OCD evidence largely comes from supervised IV or IM treatment. It does not establish efficacy or safety for unsupervised at-home compounded ketamine. FDA has warned about compounded ketamine marketed for psychiatric disorders and specifically highlighted risks when patients use products without appropriate monitoring.

What is the research status of ketamine for OCD in 2026?

The field has moved beyond isolated case reports: there are small randomized trials, repeated-dose studies, two 2026 systematic reviews, and current international guideline treatment of the topic. It remains an emerging, off-label intervention with limited long-term evidence. CANMAT/ICOCS places IV ketamine monotherapy in the third-line range, while evidence for adjunctive and intranasal approaches is insufficient for stronger recommendations.

Conclusion

Ketamine is one of the few experimental OCD treatments with replicated evidence of symptom change on the scale of hours rather than weeks. That rapid signal now appears across small controlled studies using intravenous and intramuscular racemic ketamine, and the newest systematic reviews support continued clinical research. The same evidence also shows why ketamine has not become routine OCD treatment: samples are small, results vary, acute psychoactive effects complicate trials, and sustained benefit remains uncertain.

For clinical decision-making in 2026, the most defensible position is a narrow one. IV ketamine monotherapy can be considered as a third-line option in selected severe, refractory situations within specialist care, especially when rapid response is clinically important. It should be evaluated as one component of an OCD treatment pathway that still relies on high-quality diagnosis, ERP and CBT, established pharmacotherapy, rational augmentation, level-of-care decisions, and long-term follow-up.

The key research question is no longer simply whether ketamine can make OCD symptoms move quickly. It can. The field now has to determine whether that movement can be made reliable, safe, durable, and clinically meaningful.

References

Bandeira, I. D., et al. (2022). Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review. Harvard Review of Psychiatry, 30, 135–145. PMID 35267254. DOI: 10.1097/HRP.0000000000000330.

Beaglehole, B., et al. (2025). Ketamine for treatment-resistant obsessive-compulsive disorder: Double-blind active-controlled crossover study. Journal of Psychopharmacology, 39(1), 23–28. PMID 39609659. DOI: 10.1177/02698811241301215.

Beaglehole, B., et al. (2025). Six weeks open-label oral ketamine for patients with treatment-resistant depression, post-traumatic stress disorder, or obsessive-compulsive disorder. Journal of Psychopharmacology, 39(6), 571–576. PMID 40468911. DOI: 10.1177/02698811251344710.

Bloch, M. H., et al. (2012). Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biological Psychiatry, 72(11), 964–970. PMID 22784486. DOI: 10.1016/j.biopsych.2012.05.028.

Eghdami, S., Boroon, M., Keshavarz-Akhlaghi, A.-A., & Shalbafan, M. (2026). Efficacy and tolerability of ketamine in moderate to severe obsessive-compulsive disorder: a systematic review. Psychopharmacology. Online ahead of print, August 27, 2026. PMID 42649323. DOI: 10.1007/s00213-026-07155-z.

Hauhnar, L., & Mehta, V. S. (2025). Effectiveness of Repeated Ketamine Infusions in Treatment Non-Responding Obsessive Compulsive Disorder: a Randomised Controlled Trial. European Psychiatry, 68(Suppl 1), S83–S84. DOI: 10.1192/j.eurpsy.2025.273.

Heroiu, I., et al. (2026). Ketamine for the Treatment of Obsessive-Compulsive Disorder (OCD): A Systematic Review on Efficacy and Tolerability. Clinical Neuropharmacology. Online ahead of print, June 19, 2026. PMID 42311186. DOI: 10.1097/WNF.0000000000000692.

International OCD Foundation. Ketamine and Psychedelics for Obsessive-Compulsive Disorder. Clinical overview by Christopher Pittenger, MD, PhD.

López-Rodríguez, S., et al. (2026). Repeated intranasal esketamine augmentation in treatment-resistant obsessive-compulsive disorder with comorbid major depressive disorder: a prospective case series. BMC Psychiatry, 26, 469. PMID 42036648. DOI: 10.1186/s12888-026-08119-5.

Rodriguez, C. I., et al. (2013). Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology, 38(12), 2475–2483. PMID 23783065. DOI: 10.1038/npp.2013.150.

Rodriguez, C. I., et al. (2016). Can Exposure-Based CBT Extend IV Ketamine’s Effects in Obsessive-Compulsive Disorder? Journal of Clinical Psychiatry, 77(3), 408–409. PMID 27046314. DOI: 10.4088/JCP.15l10138.

Sharma, L. P., et al. (2020). Clinical utility of repeated intravenous ketamine treatment for resistant obsessive-compulsive disorder. Asian Journal of Psychiatry, 52, 102183. PMID 32554207. DOI: 10.1016/j.ajp.2020.102183.

U.S. Food and Drug Administration. (2023). FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders.

U.S. Food and Drug Administration. (2025). Spravato (esketamine) nasal spray: Prescribing Information, revised 2025.

U.S. National Library of Medicine, DailyMed. Ketalar (ketamine hydrochloride injection): Prescribing Information.

Van Ameringen, M., et al. (2026). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) 2025 international guidelines for the management of patients with obsessive-compulsive disorder. Journal of Psychiatric Research, 199, 404–488. PMID 42441734. DOI: 10.1016/j.jpsychires.2025.12.039.